List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 1594 studies with search of: "Antibodies"
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Recruiting Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma
Conditions: Carcinoma, Renal Cell;   Melanoma
Interventions: Biological: GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody;   Biological: GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody;   Biological: GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody;   Biological: GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody;   Biological: GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody;   Biological: GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody;   Biological: GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ ) Monoclonal Antibody;   Biological: GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody
2 Withdrawn Monoclonal Antibody Therapy in Treating Patients With Advanced Solid Tumors
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: monoclonal antibody anti-anb3 integrin;   Procedure: anti-cytokine therapy;   Procedure: antiangiogenesis therapy;   Procedure: antibody therapy;   Procedure: biological response modifier therapy;   Procedure: growth factor antagonist therapy;   Procedure: monoclonal antibody therapy
3 Recruiting A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer´s Disease
Condition: Alzheimer´s Disease
Interventions: Drug: Immune Globulin Intravenous (Human), 10% (IGIV, 10%);   Drug: Immune Globulin Intravenous (Human), 10% (IGIV, 10%);   Other: Placebo solution
4 Recruiting Efficacy of High-Dose Intravenous Immunoglobulin Therapy for Hyperbilirubinemia Due Rh Hemolytic Disease
Conditions: Hyperbilirubinemia;   Erythroblastosis, Fetal
Interventions: Drug: Intravenous Immunoglobulin;   Drug: Normal saline solution
5 Active, not recruiting Monoclonal Antibody Therapy Plus Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Condition: Prostate Cancer
Interventions: Biological: filgrastim;   Biological: monoclonal antibody m170;   Drug: cyclosporine;   Drug: paclitaxel;   Procedure: peripheral blood stem cell transplantation;   Radiation: indium In 111 monoclonal antibody m170;   Radiation: yttrium Y 90 monoclonal antibody m170
6 Active, not recruiting Monoclonal Antibody Therapy, Paclitaxel, and Cyclosporine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Biological: monoclonal antibody Lym-1;   Drug: cyclosporine;   Drug: paclitaxel;   Radiation: indium In 111 monoclonal antibody Lym-1;   Radiation: yttrium Y 90 monoclonal antibody Lym-1
7 Active, not recruiting Monoclonal Antibody Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Biological: filgrastim;   Biological: monoclonal antibody Lym-1;   Drug: cyclosporine;   Drug: paclitaxel;   Procedure: peripheral blood stem cell transplantation;   Radiation: indium In 111 monoclonal antibody Lym-1;   Radiation: yttrium Y 90 monoclonal antibody Lym-1
8 Completed Testing of INSTI™ HIV-1 Antibody Test Kit in Volunteer Subjects at Risk for HIV Infection
Condition: HIV Infections
Interventions: Other: Behavioral counseling;   Device: HIV-1 Antibody Test Kit
9 Completed Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Condition: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Interventions: Drug: Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified;   Drug: Albumin (Human) 25%, USP
10 Active, not recruiting Monoclonal Antibody Therapy in Treating Patients With Advanced Cancer
Conditions: Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Precancerous/Nonmalignant Condition;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: monoclonal antibody A27.15;   Biological: monoclonal antibody E2.3
11 Completed Specific IgG Antibody in Patients With Primary Antibody Deficiencies Treated With Subcutaneous Immunoglobulin
Conditions: Common Variable Immunodeficiency;   Agammaglobulinemia
Intervention: Biological: gammaglobulin
12 Active, not recruiting Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer
Condition: Prostate Cancer
Interventions: Biological: monoclonal antibody muJ591;   Radiation: iodine I 131 monoclonal antibody muJ591
13 Terminated Intravenous Immunoglobulin After Relapse in Vasculitis
Conditions: ANCA + Vasculitides Relapsing Either Under Corticosteroid;   and Immunosuppressant Therapies or After One Year;   Post Treatment.
Intervention: Drug: Intravenous immunoglobulins (human immunoglobulins G)
14 Active, not recruiting Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
Condition: Lung Cancer
Interventions: Radiation: indium In 111 monoclonal antibody MN-14;   Radiation: yttrium Y 90 monoclonal antibody MN-14
15 Active, not recruiting Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Condition: Lung Cancer
Interventions: Radiation: indium In 111 monoclonal antibody MN-14;   Radiation: yttrium Y 90 monoclonal antibody MN-14
16 Active, not recruiting Expanded Access Study of Iodine-131 Anti-B1 Antibody
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Iodine-131 Anti-B1 Antibody
17 Completed Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Interventions: Drug: Iodine-131 Anti-B1 Antibody;   Drug: Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP)
18 Active, not recruiting Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: Iodine-131 Anti-B1 Antibody
19 Active, not recruiting Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for the Retreatment of Patients With Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Iodine-131 Anti-B1 Antibody
20 Active, not recruiting Safety and Efficacy of Iodine-131 Anti-B1 Antibody for NHL Patients With Greater Than 25% Bone Marrow Involvement
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Iodine-131 Anti-B1 Antibody

Previous Page Studies Shown (1-20) Next Page (21-40)
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
  RSS Feed for studies found by your search that were received in the last 14 days
  Download Options




U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services